Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial to Evaluate Pemetrexed Response in Relation to Tumor Alterations of Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma and Other Solid Tumors

NCT06630416 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06630416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial to Evaluate Pemetrexed Response in Relation to Tumor Alterations of Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma and Other Solid Tumors
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Recruiting
Start date
November 27, 2024
Completion date
May 10, 2030
Enrollment
64 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic bladder urothelial carcinoma, metastatic malignant solid neoplasm, mtap deletion, stage iv bladder cancer ajcc v8